Literature DB >> 16684835

An increased coronary risk is paradoxically associated with common cholesteryl ester transfer protein gene variations that relate to higher high-density lipoprotein cholesterol: a population-based study.

Susanna E Borggreve1, Hans L Hillege, Bruce H R Wolffenbuttel, Paul E de Jong, Mike W Zuurman, Gerrit van der Steege, Arie van Tol, Robin P F Dullaart.   

Abstract

BACKGROUND: Several cholesteryl ester transfer protein (CETP) polymorphisms affect high-density lipoprotein (HDL) cholesterol, but the impact of CETP gene variants on incident coronary disease in the general population is uncertain after correction for their effect on HDL cholesterol.
DESIGN: We determined relationships between the CETP -629C-->A promoter (n = 8141), the TaqIB (n = 8289), and the I405V (n = 8265) polymorphisms, serum lipids, C-reactive protein, and clinical factors with incident coronary heart disease (defined as death from or hospitalization for myocardial infarction, ischemic heart disease, or coronary intervention) during a median of 4.94 yr follow-up.
SUBJECTS: A predominantly Caucasian general population was studied.
RESULTS: HDL cholesterol was 0.08 mmol/liter higher in -629A carriers than in -629CC homozygotes (P < 0.001). The unadjusted coronary hazard was 1.26 [95% confidence interval (CI), 0.95-1.68; P = 0.11] in A carriers compared with CC homozygotes and increased to 1.46 (95% CI, 1.10-1.95; P = 0.01) after adjustment for HDL cholesterol. This effect remained after additional adjustment for apolipoprotein A-I, triglycerides, C-reactive protein, age, and gender. Likewise, the HDL-cholesterol-adjusted hazard ratio was also higher in AA than in CC homozygotes (hazard ratio, 1.72; 95% CI, 1.22-2.42; P < 0.01). Similar findings were obtained with the TaqIB polymorphism. The 405V allele was weakly associated with incident coronary heart disease after HDL cholesterol adjustment (P = 0.09).
CONCLUSIONS: A common CETP promoter polymorphism, which beneficially contributes to higher HDL cholesterol, is paradoxically associated with increased incidence of coronary disease in the general population. Thus, CETP gene variation may affect coronary risk apart from the level of HDL cholesterol.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16684835     DOI: 10.1210/jc.2005-2322

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  29 in total

1.  The conscientious judgement of a DSMB--statistical stopping rules re-examined.

Authors:  Karin Hedenmalm; Hans Melander; Gunnar Alvan
Journal:  Eur J Clin Pharmacol       Date:  2007-11-14       Impact factor: 2.953

Review 2.  Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches.

Authors:  Emil M deGoma; Rolando L deGoma; Daniel J Rader
Journal:  J Am Coll Cardiol       Date:  2008-06-10       Impact factor: 24.094

3.  Apolipoprotein B attenuates albuminuria-associated cardiovascular disease in prevention of renal and vascular endstage disease (PREVEND) participants.

Authors:  James P Corsetti; Ron T Gansevoort; Stephan J L Bakker; Charles E Sparks; Priya Vart; Robin P F Dullaart
Journal:  J Am Soc Nephrol       Date:  2014-05-22       Impact factor: 10.121

Review 4.  Novel HDL-directed pharmacotherapeutic strategies.

Authors:  Emil M Degoma; Daniel J Rader
Journal:  Nat Rev Cardiol       Date:  2011-01-18       Impact factor: 32.419

5.  Positive correlation of serum HDL cholesterol with blood mercury concentration in metabolic syndrome Korean men (analysis of KNANES 2008-2010, 2013).

Authors:  S J Park; K J Yeum; B Choi; Y S Kim; N S Joo
Journal:  J Endocrinol Invest       Date:  2016-04-23       Impact factor: 4.256

6.  Association of Cholesteryl Ester Transfer Protein (CETP) Gene -629C/A Polymorphism with Angiographically Proven Atherosclerosis.

Authors:  Anita Devi; Ritu Singh; Rajni Dawar; Sanjay Tyagi
Journal:  Indian J Clin Biochem       Date:  2016-06-11

7.  S447X variant of the lipoprotein lipase gene, lipids, and risk of coronary heart disease in 3 prospective cohort studies.

Authors:  Majken K Jensen; Eric B Rimm; Daniel Rader; Erik B Schmidt; Thorkild I A Sørensen; Ulla Vogel; Kim Overvad; Kenneth J Mukamal
Journal:  Am Heart J       Date:  2009-02       Impact factor: 4.749

8.  Cholesteryl ester transfer protein gene polymorphisms and longevity syndrome.

Authors:  Genovefa Kolovou; Marianna Stamatelatou; Katherine Anagnostopoulou; Peggy Kostakou; Vana Kolovou; Constantinos Mihas; Ioannis Vasiliadis; Olga Diakoumakou; Dimitri P Mikhailidis; Dennis V Cokkinos
Journal:  Open Cardiovasc Med J       Date:  2010-01-29

9.  Cardiovascular risk associated with interactions among polymorphisms in genes from the renin-angiotensin, bradykinin, and fibrinolytic systems.

Authors:  John P Bentley; Folkert W Asselbergs; Christopher S Coffey; Patricia R Hebert; Jason H Moore; Hans L Hillege; Wiek H van Gilst
Journal:  PLoS One       Date:  2010-09-15       Impact factor: 3.240

10.  Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community.

Authors:  Ramachandran S Vasan; Michael J Pencina; Sander J Robins; Justin P Zachariah; Guneet Kaur; Ralph B D'Agostino; Jose M Ordovas
Journal:  Circulation       Date:  2009-12-15       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.